Remarkably, the infusion of BTG2-deficient mast cells reduced chemotherapy efficacy and increased lymph node metastasis in the breast cancer mouse model, compared to untreated mast cells. The gene discussed is BTG2; the disease is metastatic malignant neoplasm in the lymph nodes.